Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
Phase 1
Not yet recruiting
- Conditions
- Relapsed/Refractory Indolent NHL
- Interventions
- Drug: Linperlisib ； Rituximab
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06981988
A Clinical Study of HRS-6209 in Combination With Letrozole in Patients With Breast Cancer
Phase 1
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: HRS-6209 Capsules
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06974929
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Relative Bioavailability Study of HRG2010 in Healthy Subjects
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: HRG2010 Capsule, Sinemet®, Madopar®
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06976346
- Locations
- 🇨🇳
Shandong Province Qianfoshan Hospital, Jinan, Shandong, China
A Trial of SHR7280 in Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- EndometriosisUterine FibroidsAssisted Reproduction
- Interventions
- Drug: SHR7280 TabletDrug: SHR7280 Placebo Tablet
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06969664
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- EndometriosisUterine FibroidsAssisted Reproduction
- Interventions
- Drug: SHR7280 Tablets
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06949124
- Locations
- 🇨🇳
Zhongnan hospital of Wuhan University, Wuhan, Hubei, China
A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- Skeletal Muscle Relaxation
- Interventions
- Drug: HRS-9190 for Injection
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06932315
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT06925581
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Relative Bioavailability Study of HR19042 in Healthy Subjects
Phase 1
Completed
- Conditions
- Primary IgA Nephropathy; Autoimmune Hepatitis
- Interventions
- Drug: HR19042 Capsule, Tarpeyo®, Budenofalk®
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06922305
- Locations
- 🇨🇳
Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study
Phase 2
Not yet recruiting
- Conditions
- Psoriatic Subjects
- Interventions
- Drug: RSS0393 ointmentDrug: RSS0393 ointment placebo
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 147
- Registration Number
- NCT06918743
A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT06906731
- Locations
- 🇨🇳
Harbin Medical University cancer hospital, Harbin, Heilongjiang, China
© Copyright 2025. All Rights Reserved by MedPath